Methods and Analysis of Biological Contaminants in the Biomanufacturing Industry
-
Published:2023-05-18
Issue:5
Volume:11
Page:298
-
ISSN:2227-9040
-
Container-title:Chemosensors
-
language:en
-
Short-container-title:Chemosensors
Author:
Janghorban Mohammad1ORCID, Kazemi Sara1ORCID, Tormon Rigel2, Ngaju Philippa1ORCID, Pandey Richa13ORCID
Affiliation:
1. Department of Biomedical Engineering, University of Calgary, Calgary, AB T2N 1N4, Canada 2. Department of Chemical Engineering, University of Calgary, Calgary, AB T2N 1N4, Canada 3. Hotchkiss Brain Institute, University of Calgary, Calgary, AB T2N 1N4, Canada
Abstract
The advent of bioprocessing has revolutionized the biomanufacturing industry, leading to the rise of biotherapeutics derived from biologic products such as chimeric antigen receptor (CAR) T-cells used for targeted cancer treatment and the Vero cell line for the production of viral vectors and vaccines. Despite these promising developments, most biologic products are characterized by fragile macromolecular structures that are heterogenous with a purity profile that varies with each batch making them susceptible to microorganism contamination. Regulatory oversight of biologic products is imperative to ensure adherence to good manufacturing practices and compliance with quality management systems. Current quality assurance protocols during production include monoclonality during cell line development, real-time monitoring of process parameters, flow cytometry for microbial monitoring, polymerase chain reaction, and immunoassay techniques to amplify DNA sequences related to bacterial or biological contaminants. FDA guidance recommends the implementation of process analytical technology within biomanufacturing production to measure critical quality parameters, which includes screening for potential biological contamination. Future advancements in bioprocess monitoring and control should capitalize on providing cheap, real-time, and sensitive detection. Biosensors, mass spectrometry, and polymerase chain reaction present robust, rapid, and real-time capabilities for multiplexed detection of contaminant analytes and have shown promise in meeting these needs. This review discusses the main biological contaminants of bioprocesses, European Union and FDA regulatory guidelines for monitoring and control within biologics production, existing methods and their limitations, and future advancements for biological contamination detection.
Funder
VPR catalyst University of Calgary Startup grant, University of Calgary
Subject
Physical and Theoretical Chemistry,Analytical Chemistry
Reference84 articles.
1. Jarrige, M., Frank, E., Herardot, E., Martineau, S., Darle, A., Benabides, M., Domingues, S., Chose, O., Habeler, W., and Lorant, J. (2021). The Future of Regenerative Medicine: Cell Therapy Using Pluripotent Stem Cells and Acellular Therapies Based on Extracellular Vesicles. Cells, 10. 2. Govardhanagiri, S., Bethi, S., and Nagaraju, G.P. (2019). Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy, Elsevier. 3. A Fully Integrated Online Platform for Real Time Monitoring of Multiple Product Quality Attributes in Bio-Pharmaceutical Processes for Monoclonal Antibody Therapeutics;Liu;J. Pharm. Sci.,2022 4. Zmievskaya, E., Valiullina, A., Ganeeva, I., Petukhov, A., Rizvanov, A., and Bulatov, E. (2021). Application of CAR-T Cell Therapy beyond Oncology: Autoimmune Diseases and Viral Infections. Biomedicines, 9. 5. Adventitious Agent Detection Methods in Bio-Pharmaceutical Applications with a Focus on Viruses, Bacteria, and Mycoplasma;Morris;Curr. Opin. Biotechnol.,2021
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|